It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
When exposed to nutrient excess and insulin resistance, pancreatic β-cells undergo adaptive changes in order to maintain glucose homeostasis. The role that growth control genes, highly expressed in early pancreas development, might exert in programming β-cell plasticity in later life is a poorly studied area. The imprinted Igf2 (insulin-like growth factor 2) gene is highly transcribed during early life and has been identified in recent genome-wide association studies as a type 2 diabetes susceptibility gene in humans. Hence, here we investigate the long-term phenotypic metabolic consequences of conditional Igf2 deletion in pancreatic β-cells (Igf2βKO) in mice. We show that autocrine actions of IGF2 are not critical for β-cell development, or for the early post-natal wave of β-cell remodelling. Additionally, adult Igf2βKO mice maintain glucose homeostasis when fed a chow diet. However, pregnant Igf2βKO females become hyperglycemic and hyperinsulinemic, and their conceptuses exhibit hyperinsulinemia and placentomegalia. Insulin resistance induced by congenital leptin deficiency also renders Igf2βKO females more hyperglycaemic compared to leptin-deficient controls. Upon high-fat diet feeding, Igf2βKO females are less susceptible to develop insulin resistance. Based on these findings, we conclude that in female mice, autocrine actions of β-cell IGF2 during early development determine their adaptive capacity in adult life.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Cambridge, Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Institute of Metabolic Science, Addenbrookes Hospital, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Cambridge Biomedical Research Centre, Department of Obstetrics and Gynaecology and National Institute for Health Research, Cambridge, UK (GRID:grid.454369.9); University of Cambridge, Centre for Trophoblast Research, Department of Physiology, Development and Neuroscience, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
2 University of Cambridge, Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Institute of Metabolic Science, Addenbrookes Hospital, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Cambridge Biomedical Research Centre, Department of Obstetrics and Gynaecology and National Institute for Health Research, Cambridge, UK (GRID:grid.454369.9); Novo Nordisk A/S, Bagsværd, Denmark (GRID:grid.425956.9) (ISNI:0000 0001 2264 864X)
3 University of Cambridge, Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Institute of Metabolic Science, Addenbrookes Hospital, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
4 Universidad Rey Juan Carlos, Área de Bioquímica y Biología Molecular, Departamento de Ciencias Básicas de la Salud, Alcorcón, Madrid, Spain (GRID:grid.28479.30) (ISNI:0000 0001 2206 5938); Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Headington, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 Universidad Rey Juan Carlos, Área de Bioquímica y Biología Molecular, Departamento de Ciencias Básicas de la Salud, Alcorcón, Madrid, Spain (GRID:grid.28479.30) (ISNI:0000 0001 2206 5938)
6 University of Cambridge, Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Institute of Metabolic Science, Addenbrookes Hospital, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Welcome Trust Sanger Institute, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Cambridge University Nanjing Centre of Technology and Innovation, Nanjing, People’s Republic of China (GRID:grid.10306.34)